Change in Fatigue and Correlations with Clinical Outcome in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib in the Bolt Study
Alex Guminski(The University of Sydney), Reinhard Dummer(University Hospital of Zurich), Uwe Trefzer(Goethe University Frankfurt), R. Herd(Glasgow Royal Infirmary), Lewis Kd(University of Colorado Anschutz Medical Campus), Katherine Houghton(RTI Health Solutions), Dalila Sellami(Daiichi Sankyo (United States)), P. Combemale(Centre Léon Bérard), Luc Dirix(European Organisation for Research and Treatment of Cancer), D Stull(RTI Health Solutions), John T. Lear(Salford Royal Hospital), Ragini R. Kudchadkar, MR Migden(The University of Texas MD Anderson Cancer Center), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k